Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. provides comprehensive kidney care through a global dialysis and care-delivery network. Company news commonly covers quarterly operating results, revenue per treatment, patient care costs, reimbursement trends, share repurchases and investor conference participation.
Updates also address DaVita's value-based kidney care programs, coordinated care arrangements, and services that support patients across stages and settings of kidney disease, including home support, outpatient dialysis centers, hospitals, skilled nursing facilities and transplantation-related care.
DaVita has reported significant achievements in kidney care for 2022, highlighting a record referral rate for transplants with over 92,000 patients referred and approximately 7,800 kidney transplants performed. The company also launched DaVita Care Connect®, enhancing remote patient monitoring, and expanded its Chronic Kidney Disease & Rare Disease Network to promote diversity in research. DaVita Integrated Kidney Care (IKC) extended services to over 33,000 new patients and formed partnerships to enhance patient care. Furthermore, DaVita committed $15 million to support economic mobility and received multiple awards recognizing its workplace and sustainability efforts.
On December 20, 2022, DaVita announced its inaugural Move It with Purpose (MIWP) event, which raised over $650,000 for the nonprofit Bridge of Life. This fundraising effort has generated nearly $15 million since 2007, enhancing kidney care globally. Funds from this year's event will support increasing access to kidney transplants and dialysis, particularly in underserved areas like Guatemala. MIWP encouraged participation from the kidney care community, logging physical activities from October 1-November 15, with DaVita donating $1 for every mile logged, up to $250,000.
DaVita Clinical Research showcased its latest findings at ASN Kidney Week 2022, emphasizing advancements in kidney transplantation and patient care equity. The introduction of the Chronic Kidney Disease (CKD) & Rare Disease Network aims to enhance access to decentralized research and trials, increasing diversity in participant demographics. Key research topics presented include end-of-life care preferences among dialysis patients and the social factors affecting transplant waitlisting. DaVita continues to innovate in kidney care, aiming for better patient outcomes and treatment options.
DaVita reported challenging third-quarter results for the period ending September 30, 2022, with consolidated revenues of $2.949 billion and diluted earnings per share at $1.13. Labor pressures and COVID-related volume declines adversely impacted their financials. Operating income fell to $312 million, down from $433 million in the previous quarter. While the company repurchased 2.1 million shares, net income was significantly reduced to $105 million compared to $225 million in the prior quarter. Despite these challenges, DaVita remains confident in its kidney care platform.
DaVita Inc. (NYSE: DVA) announced its quarterly conference call scheduled for October 28, 2022, at 8:30 a.m. ET, to discuss its third quarter results. The results will be released before the market opens on the same day. The call will be available via webcast on DaVita's IR webpage. As of June 30, 2022, DaVita served 198,000 patients at 2,808 outpatient dialysis centers in the U.S. and operates 349 outpatient dialysis centers in 11 countries. The company continues to focus on improving kidney care and quality of life for patients globally.
The DaVita Giving Foundation has announced a $1.4 million grant to the Food Is Medicine Coalition to support medically-tailored meals for individuals with chronic medical conditions. This initiative aims to address food insecurity, which affects 10% of the U.S. population, particularly impacting kidney health. The grant will provide over 100,000 meals through nonprofit organizations in Sacramento, Los Angeles, Minneapolis, and Orlando. DaVita's commitment reinforces its strategy to enhance community health and patient care.
On September 13, 2022, DaVita Inc. announced the appointment of Adam H. Schechter as an independent director to its Board, effective September 20, 2022. Schechter, currently CEO of Labcorp, has over 30 years of experience in healthcare, previously holding leadership roles at Merck & Co.. His extensive experience in the healthcare ecosystem aims to enhance DaVita's mission of improved patient care. Mr. Schechter will also serve on the Audit and Compliance & Quality Committees. DaVita is a leading kidney care provider, serving 198,000 patients at 2,810 centers in the U.S.
Federman & Sherwood has launched an investigation into DaVita, Inc. (NYSE: DVA) due to a significant data breach confirmed on September 8, 2022. The breach involved unauthorized access to sensitive consumer data, affecting individuals' names, addresses, Social Security numbers, medical, and health insurance information. DaVita operates approximately 2,816 outpatient dialysis centers across the United States, raising concerns over consumer data protection and potential legal implications from the breach.
DaVita Inc. reported its financial results for Q2 2022, highlighting consolidated revenues of $2.927 billion and a net income of $225 million.
Operating income reached $433 million, with diluted EPS at $2.30. Despite challenges like a global pandemic and supply chain issues, performance showed resilience with 7,269,160 total dialysis treatments conducted.
The company repurchased 3.9 million shares at an average cost of $95.56 per share, reflecting a commitment to shareholder value.
The American Diabetes Association (ADA) and DaVita announced the launch of a digital platform aimed at combating diabetes-related kidney complications on July 25, 2022. This initiative targets the one in seven U.S. adults affected by diabetes, which is the leading cause of chronic kidney disease (CKD). The platform offers resources including Kidney Smart classes, meal planning, and physician engagement tips to empower diabetes patients. Dr. Robert Gabbay of ADA emphasized the importance of understanding the diabetes-kidney connection to improve health outcomes.